PD-L1 expression in neuroendocrine tumors of the lung

Tsuruoka, Kenjiro; Horinouchi, Hidehito; Goto, Yasushi; Kanda, Shintaro; Fujiwara, Yutaka; Nokihara, Hiroshi; Yamamoto, Noboru; Asakura, Keisuke; Nakagawa, Kazuo; Sakurai, Hiroyuki; Watanabe, Shun; Tsuta, Koji; Ohe, Yuichiro

doi:10.1016/j.lungcan.2017.03.006

Cited by 100 publications

(80 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, data regarding PD-L1 expression in pulmonary neuroendocrine tumors are sparse, only fragmented data are available especially in carcinoids and LCNEC (Fan et al 2016, Tsuruoka et al 2017. Recently, some studies reported on PD-L1 immunoreactivity in mostly small cohorts of SCLC (Ishii et al 2015, Schultheis et al 2015, Berghoff et al 2016, Fan et al 2016, Miao et al 2016, Tsuruoka et al 2017, Yu et al 2017. However, the reported incidence and localization of PD-L1 expression varied considerably, probably due to the fact that differing antibodies were used and/or variable cutoff values were applied.…”

Section: Introductionmentioning

confidence: 99%

Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors

Kasajima¹,

Ishikawa²,

Iwata³

et al. 2018

Endocrine-Related Cancer

View full text Add to dashboard Cite

In the light of novel cancer immune therapies, the status of antitumor inflammatory response and its regulation has gained much attention in patients with lung cancer. Ample datasets exist for non-small-cell lung cancer, but those for pulmonary neuroendocrine tumors are scarce and controversial. Here, tumor-associated inflammation, CD8+ cell infiltration and PD-L1 status were evaluated in a cohort of 57 resected carcinoids and 185 resected neuroendocrine carcinomas of the lung (58 large cell carcinomas and 127 small cell carcinomas). Data were correlated with clinicopathological factors and survival. Moderate or high tumor-associated inflammation was detected in 4 carcinoids (7%) and in 37 neuroendocrine carcinomas (20%). PD-L1 immunoreactivity was seen in immune cells of 73 (39%) neuroendocrine carcinomas, while tumor cells were labeled in 21 (11%) cases. Inflammatory cells and tumor cells in carcinoids lacked any PD-L1 expression. In neuroendocrine carcinomas, PD-L1 positivity in immune cells, but not in tumor cells, was associated with intratumoral CD8+ cell infiltration ( < 0.001), as well as with the severity of tumor-associated inflammation ( < 0.001). In neuroendocrine carcinomas, tumor-associated inflammation and PD-L1 positivity in immune cells correlated with prolonged survival and the latter factor was also an independent prognosticator ( < 0.01, hazard ratio 0.4 for overall survival, < 0.001 hazard ratio 0.4 for disease-free survival). Taken together, in neuroendocrine tumors, antitumor inflammatory response and PD-L1 expression are largely restricted to neuroendocrine carcinomas, and in this tumor entity, PD-L1 expression in inflammatory cells is positively correlated to patient survival.

show abstract

Section: Introductionmentioning

confidence: 99%

Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors

Kasajima¹,

Ishikawa²,

Iwata³

et al. 2018

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…None of the TC and AC were found to be positive for PD-L1 expression. 5.8% (n = 4) SCLC and 10.4% (n = 11) LCNEC patients were found PD-L1 positive [27]. It seems the PD-L1 expression is variable among neuroendocrine tumors and high grade neuroendocrine tumors might have higher odds of being PD-L1 positive especially gastroenteropancreatic origin.…”

Section: Modern Immuno-oncology and Netsmentioning

confidence: 95%

Untitled

2018

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Initially, PD-L1 was described in SCLC (Schultheis et al 2015), in lung typical-atypical carcinoids and in large cell neuroendocrine carcinoma (Tsuruoka et al 2017). Subsequently, its presence was described and related with clinical features in other NENs; specifically, PDL-1 has been correlated with tumor stage and histological type in PNENs, as well as with worse survival (Fan et al 2016).…”

Section: Biomarkers For Immune Therapymentioning

confidence: 99%

Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers

Herrera‐Martínez

Hofland

Moreno

et al. 2019

Endocrine-Related Cancer

View full text Add to dashboard Cite

Some biomarkers for functioning and non-functioning neuroendocrine neoplasms (NENs) are currently available. Despite their application in clinical practice, results should be interpreted cautiously. Considering the variable sensitivity and specificity of these parameters, there is an unmet need for novel biomarkers to improve diagnosis and predict patient outcome. Nowadays, several new biomarkers are being evaluated and may become future tools for the management of NENs. These biomarkers include (1) peptides and growth factors; (2) DNA and RNA markers based on genomics analysis, for example, the so-called NET test, which has been developed for analyzing gene transcripts in circulating blood; (3) circulating tumor/endothelial/progenitor cells or cell-free tumor DNA, which represent minimally invasive methods that would provide additional information for monitoring treatment response and (4) improved imaging techniques with novel radiolabeled somatostatin analogs or peptides. Below we summarize some future directions in the development of novel diagnostic and predictive/prognostic biomarkers in NENs. This review is focused on circulating and selected tissue markers.

show abstract

PD-L1 expression in neuroendocrine tumors of the lung

Abstract: PD-L1 expression was apparent in 10.4% of LCNEC and 5.8% of SCLC tumors, and was not observed in carcinoid tumors.

Cited by 100 publications

References 39 publications

Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors

Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors

Untitled

Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers

Contact Info

Product

Resources

About